About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- 179 US adults with obesity or overweight, without type 2 diabetes
- Sample size
- 179
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Phase 2; sponsor-funded (Eli Lilly). The primary endpoint was at 32 weeks. Abstract read via Europe PMC; full text not read.
Cited in
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.